Chemclin Diagnostics Co., Ltd. Class A

As of June 30, 2026, Chemclin Diagnostics Co., Ltd. Class A carries a market capitalization of 2.28B, placing it among publicly traded companies globally. Its enterprise value stands at 2.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Chemclin Diagnostics Co., Ltd. Class A has 401.11M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Chemclin Diagnostics Co., Ltd. Class A maintains a current ratio of 4.16, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Chemclin Diagnostics Co., Ltd. Class A recorded 4.22M in income tax expense.

As of the close on October 23, 2026, Chemclin Diagnostics Co., Ltd. Class A's stock has declined approximately 23.54% over the past 52 weeks. The 50-day moving average sits at 6.35, while the 200-day moving average is 6.87.

As of June 30, 2026, Chemclin Diagnostics Co., Ltd. Class A holds 395.79M in cash and equivalents against 229.85M in total debt, resulting in a net debt position of -4.07M. Total book value stands at 1.43B, with working capital of 498.53M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Chemclin Diagnostics Co., Ltd. Class A paid dividends of 0.01 per share.